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Soluble guanylyl cyclase (sGC) is a ubiquitously expressed
enzyme that is highly expressed in the lung. Stimulation
of sGC by nitric oxide (NO) increases the conversion of
GTP to cGMP, thereby, causing airway smooth muscle
relaxation. To determine whether sGC expression is
reduced in an animal model of inflammatory airway dis-
ease and, therefore, contributes to airway hyperreactivity
(AHR), mice were sensitized and challenged with ovalbu-
min (OVA). Histological and biochemical analyses con-
firmed the presence of inflammation in the lungs of OVA-
challenged mice that was characterized by increased eosi-
nophil infiltration, mucus production and high inter-
leukin-13 levels. Moreover, OVA-challenged mice
exhibited increased airway reactivity to methacholine
inhalation. Steady-state mRNA levels for all sGC subunits
(α1, α2 and β1) were reduced in the lungs of OVA mice
by 60–80%, as estimated by real-time PCR. The changes in
sGC expression extended to the protein level where α1, α2
and β1 were reduced by 50–70%, as determined by west-
ern blotting. Reduced α1 and β1 expression in animals
with asthma was confirmed by immunohistochemistry
and showed to occur in epithelial and smooth muscle
cells. To study if AHR and/or inflammation occur follow-
ing sGC inhibition in naïve animals, mice we treated with
the selective sGC inhibitor 1H-[1,2,4] oxydiazolo[4,3-
ea]quinoxalin-1-one (ODQ). Such treatment led to bron-
chial hyperreactivity to methacholine. However, in the
bronchoalveolar lavage fluid of ODQ-treated mice only a
small increase in macrophage number was detected, with-
out changes in IL-13 levels or eosinophil infiltration. We
conclude that sGC expression is reduced in an animal
model of asthma contributing to the observed AHR.
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